MOTS-c: Published Research

Introduction

MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) entered the published literature in 2015 with a characterization study in Cell Metabolism [1]. Since then, a growing body of peer-reviewed research has examined the peptide's molecular mechanisms, tissue distribution, circulating levels in human cohorts, and roles in models of metabolic stress, muscle physiology, and inflammatory response. All findings below are attributed to their source investigations; no independent claims are made by SpartaLabs. Mechanistic context for these studies is covered in the MOTS-c mechanism of action article.

Methodology Types Represented in the Literature

Published MOTS-c research spans in vitro work in human cell lines (HEK293, primary myocytes, epithelial and immune cell types), rodent studies using diet-induced obesity, genetic obesity, aging, and exercise paradigms, and human cross-sectional measurements of endogenous MOTS-c in plasma or skeletal muscle biopsy material. Human interventional pharmacology represents an active frontier that has yet to be reported in peer-reviewed form, making the existing literature a rich foundation for future clinical research design.

Summary of Key Published Studies

Lee et al. (2015) — Discovery and Preclinical Metabolic Characterization

The foundational study by Lee, Zeng, Drew, Sallam, and colleagues (USC and the National Institute on Aging) identified MOTS-c from a systematic screen of mitochondrial open reading frames [1]. Synthetic MOTS-c in HEK293 cell culture produced a greater-than-20-fold accumulation of endogenous AICAR, consistent with folate cycle inhibition; AMPK activation was observed in both HEK293 cells and mouse skeletal muscle following peripheral administration.

In rodent experiments across normal-chow, high-fat-diet, and genetically obese (ob/ob) models, MOTS-c-treated animals displayed altered glucose tolerance, adiposity, and insulin tolerance outcomes versus vehicle controls. Effects were dependent on intact skeletal muscle AMPK signaling. The authors characterized these as preclinical findings and did not extend conclusions to human therapeutic potential.

Findings from research models do not establish safety or efficacy in humans. SpartaLabs makes no claims about the use of this compound.

Kim et al. (2018) — Nuclear Translocation and Retrograde Signaling

Kim, Son, Benayoun, and Lee published a 2018 Cell Metabolism paper demonstrating that MOTS-c could translocate from the cytoplasm to the nucleus in response to glucose restriction, serum deprivation, and oxidative stress, with nuclear accumulation detected within 30 minutes of stress induction [2]. In the nucleus, MOTS-c was found to bind antioxidant response element (ARE) sequences and interact with NRF2. RNA-seq profiling showed differential expression of a broad stress-response gene set in MOTS-c-treated versus control cells. Pharmacological AMPK inhibition attenuated nuclear localization. The authors framed this as mitochondrial-nuclear retrograde communication—one of the first demonstrations that a mitochondrially encoded molecule participates directly in nuclear gene regulation under stress.

Kim, Miller, Mehta et al. (2019) — Metabolomics in Mice

A 2019 Physiological Reports study from the USC/Cohen group used plasma metabolomics in mice to characterize the systemic footprint of MOTS-c administration [3]. Three pathways—sphingolipid metabolism, monoacylglycerol metabolism, and dicarboxylate metabolism—were reported at lower levels in MOTS-c-treated animals relative to controls. The authors noted that these pathways are elevated in published metabolomics profiling of obese and type 2 diabetic rodent models, and proposed a mechanistic link to the insulin sensitivity changes previously reported by Lee et al. (2015), while identifying causality determination as a direction for future work.

Reynolds et al. (2021) — Exercise, Aging, and Skeletal Muscle

A 2021 Nature Communications publication by Reynolds, Lai, Woodhead, and colleagues—including Cohen and Lee—examined MOTS-c, exercise, and age in both mouse models and human subjects [4]. In mouse experiments, MOTS-c administration was associated with higher grip strength and running capacity outcomes across young, middle-aged, and old animals versus vehicle controls, with effects described as larger in older animals for several parameters.

The study also included 10 healthy young men undergoing an acute stationary cycling bout; skeletal muscle biopsy analysis revealed an approximately 11.9-fold rise in intramuscular MOTS-c expression and an approximately 1.6-fold rise in circulating plasma levels. The authors described these findings as consistent with a role for endogenous MOTS-c in physiological adaptation to exercise.

Zhu et al. (2024) — CK2 as a Direct Molecular Target

A 2024 iScience study by Zhu, Qian, Joly, Lu, Mehta, Cohen, and Lee reported direct MOTS-c binding to casein kinase 2 (CK2) via pull-down assays and cell-free kinase activity systems [5]. MOTS-c activated CK2 in muscle but suppressed it in adipose tissue, mediated by differential CK2-interacting protein partners at each site. The study also identified a naturally occurring human sequence variant, K14Q MOTS-c, with reduced CK2 binding; male carriers in a genotyped cohort showed a statistically higher association with sarcopenia and type 2 diabetes in an age- and physical-activity-dependent manner. The authors interpreted this as the strongest human genetic evidence to date linking endogenous MOTS-c-CK2 signaling to musculoskeletal metabolic phenotypes.

Zhang et al. (2024) — NRF2-Dependent Tissue Protection in a Radiation Model

A 2024 Antioxidants paper by Zhang, Huang, and colleagues examined MOTS-c in a rodent radiation-induced pneumonitis model [6]. Treated animals showed lower lung tissue injury scores, reduced inflammatory cytokines (IL-1β, IL-6, TNFα), and attenuated oxidative stress markers compared with irradiated controls. Addition of NRF2 pathway inhibitor ML385 blunted these effects; in vitro experiments with irradiated alveolar epithelial cells replicated the NRF2-dependence finding. All observations were in animal or cell models; the authors identified human relevance as a direction for future investigation.

Human Observational Studies on Circulating MOTS-c

Several independent groups have published cross-sectional analyses of circulating MOTS-c in human cohorts. Fuku and colleagues reported intramuscular MOTS-c approximately 1.5-fold higher in older (70–81 years) and middle-aged (45–55 years) men versus young men (18–30 years), while circulating plasma levels showed the inverse pattern [7]. The authors reported a positive correlation between plasma MOTS-c and muscle quality in the older cohort, and noted a connection to MT-RNR1 variants previously associated with longevity in Japanese centenarian cohorts—a hypothesis that subsequent genetic research has continued to investigate.

A 2023 study in the International Journal of Molecular Sciences reported positive associations between serum MOTS-c concentrations and lower-body muscle strength measures in a small cohort, while finding no significant correlation with maximal oxygen uptake (VO₂max) [8]. Both observational datasets inform the design of future interventional investigations.

Active Research Frontier

The MOTS-c literature continues to expand across several productive directions: human interventional pharmacokinetics, the interplay between the three identified molecular pathways (folate-AICAR-AMPK, CK2 binding, NRF2-dependent nuclear gene regulation), and characterization of any cell-surface uptake receptor mediating tissue selectivity. The 2023 review by Wan and colleagues provides a comprehensive synthesis framing these as the field's highest-priority research opportunities [9]. Published research on NAD+ covers another active area in mitochondrial metabolic signaling that intersects with some of the same cellular energy pathways. Researchers sourcing material for these investigations can review the MOTS-c product page for current batch documentation.

References

1. Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H, Hevener AL, de Cabo R, Cohen P. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015 Mar 3;21(3):443–454. doi: 10.1016/j.cmet.2015.02.009. PMID: 25738459. https://pubmed.ncbi.nlm.nih.gov/25738459/

2. Kim KH, Son JM, Benayoun BA, Lee C. The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. Cell Metab. 2018 Sep 4;28(3):516–524.e7. doi: 10.1016/j.cmet.2018.06.015. PMID: 29983246. https://pubmed.ncbi.nlm.nih.gov/29983246/

3. Kim SJ, Miller B, Mehta HH, Xiao J, Wan J, Arpawong TE, Yen K, Cohen P. The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity. Physiol Rep. 2019 Jul;7(13):e14171. doi: 10.14814/phy2.14171. PMID: 31318170. https://pubmed.ncbi.nlm.nih.gov/31318170/

4. Reynolds JC, Lai RW, Woodhead JST, Joly JH, Mitchell CJ, Cameron-Smith D, Lu R, Cohen P, Graham NA, Benayoun BA, Merry TL, Lee C. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021 Jan 20;12(1):470. doi: 10.1038/s41467-020-20790-0. PMID: 33473109. https://pubmed.ncbi.nlm.nih.gov/33473109/

5. Zhu Z, Qian M, Joly JH, Lu R, Mehta HH, Cohen P, Lee C. MOTS-c modulates skeletal muscle function by directly binding and activating CK2. iScience. 2024 Oct 19;27(11):111215. doi: 10.1016/j.isci.2024.111215. PMID: 39559755. https://pubmed.ncbi.nlm.nih.gov/39559755/

6. Zhang Y, Huang J, Zhang Y, Jiang F, Li S, He S, Sun J, Chen D, Tong Y, Pang Q, Wu Y. The mitochondrial-derived peptide MOTS-c alleviates radiation pneumonitis via an Nrf2-dependent mechanism. Antioxidants (Basel). 2024 May 17;13(5):613. doi: 10.3390/antiox13050613. PMID: 38790718. https://pubmed.ncbi.nlm.nih.gov/38790718/

7. Fuku N, Pareja-Galeano H, Zempo H, Alis R, Arai Y, Lucia A, Hirose N. The mitochondrial-derived peptide MOTS-c: a player in exceptional longevity? Aging Cell. 2015 Dec;14(6):921–923. doi: 10.1111/acel.12389. PMID: 26332820. https://pubmed.ncbi.nlm.nih.gov/26332820/

8. Liao YH, Lin CE, Tsai JR, Lee CH, Kuo WW, Huang CY. MOTS-c serum concentration positively correlates with lower-body muscle strength and is not related to maximal oxygen uptake—a preliminary study. Int J Mol Sci. 2023 Sep 27;24(19):14644. doi: 10.3390/ijms241914644. PMID: 37834090. https://pubmed.ncbi.nlm.nih.gov/37834090/

9. Wan W, Zhang L, Lin Y, Rao X, Wang X, Hua F, Ying J. Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging. J Transl Med. 2023 Jan 20;21(1):36. doi: 10.1186/s12967-023-03885-2. PMID: 36670507. https://pubmed.ncbi.nlm.nih.gov/36670507/